Tirzepatide versus shorter peptides Shorter peptides like BPC-157 (15 amino acids) are generally more stable than tirzepatide (39 amino acids) at room temperature
Red Flags to Avoid No COA available, or a COA that won't load / is image-only with no lab name Batch numbers that don't match between COA and vial Purity claimed with no supporting HPLC chromatogram Marketing that presents the retracted "seven orders of magnitude more potent than BDNF" figure as settled fact (see the evidence section below) Human dosing instructions or therapeutic claims on the listing a tell that the seller is ignoring RUO rules Vendor copy citing a "12.8-day half-life" as established this figure appears only in vendor marketing, with no verifiable peer-reviewed source A clean COA verifies that the powder is what the label says
It should include: Batch number and lot code Testing methods (HPLC, mass spec, LAL endotoxin) Numeric results and acceptance criteria Analysts signature and date Look for at least 98% purity for clinical use
Notwithstanding any variability between peptide providers, you can expect your GHK-Cu therapy, for common GHK-Cu use cases, to proceed as follows: Youll notice from the table that GHK-Cu is cycled, a common practice with peptides
BAC water is commonly used for reconstituting multi-dose injectable drugs such as peptides